Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, 1991 Marcus Avenue, Suite 300, New Hyde Park, NY, 11042, USA.
Zema Consulting, Madison, AL, 35757, USA.
Br J Dermatol. 2022 Aug;187(2):203-210. doi: 10.1111/bjd.21236. Epub 2022 May 22.
Few validated instruments exist for use in hidradenitis suppurativa (HS) trials.
To develop a novel HS Investigator Global Assessment (HS-IGA) and to validate its psychometric properties.
Development of HS-IGA involved discussion among stakeholders, including patients, within HISTORIC. Data from replicate phase III randomized controlled trials evaluating HS treatment were utilized. Multivariate models identified lesion type and body region as variables of importance. Classification and regression trees for ordinal responses were built. Validation included assessment of test-retest reliability, predictive validity, responsiveness and clinical meaningfulness.
There were 3024 unique measurements available in PIONEER I. Mean and median lesion counts by region were largely <10 and were highest in axillary and inguinal regions. The mean and median number of regions involved were ≤ 3 for individual lesions and combinations. Regardless of lesion type, axillary and inguinal regions most influenced the HS-IGA score. Accordingly, regions were combined into a six-point IGA based on the maximum lesion number in either upper or lower body regions with a score of 0 (0-1 lesions), 1 (2-5), 2 (6-10), 3 (11-15), 4 (16-20) and 5 (≥ 20 lesions). The intraclass correlation coefficient for test-retest reliability was 0·91 (95% confidence interval 0·87-0·94). Spearman's rank order correlations (SROCs) with HS-PGA and Hidradenitis Suppurativa Clinical Response (HiSCR) were 0·73 and 0·51, respectively (P < 0·001 for both comparisons). SROCs with Dermatology Life Quality Index (DLQI), pain numerical rating scale and HS-QoL were 0·42, 0·34 and -0·25, respectively (P < 0·001 for all comparisons). HS-IGA was responsive at weeks 12 and 36. Predictive convergent validity was very good with HS-PGA (area under the curve = 0·89) and with HiSCR (area under the curve = 0·82). Predictive divergent validity was low with DLQI and HS-QoL.
HS-IGA has moderate-to-strong psychometric properties and is simple to calculate.
目前用于化脓性汗腺炎(HS)试验的经过验证的工具很少。
开发一种新的化脓性汗腺炎研究者全球评估(HS-IGA)并验证其心理测量特性。
HS-IGA 的开发涉及包括患者在内的利益相关者之间的讨论,该研究是在 HISTORIC 中进行的。利用了评估 HS 治疗的重复 III 期随机对照试验的数据。多变量模型确定了病变类型和身体区域是重要的变量。对有序反应进行分类和回归树构建。验证包括测试-重测信度、预测有效性、反应性和临床意义的评估。
在 PIONEER I 中可获得 3024 个独特的测量值。按区域划分的平均和中位数病变计数大多<10,且在腋窝和腹股沟区域最高。单个病变和组合涉及的平均和中位数区域数均≤3。无论病变类型如何,腋窝和腹股沟区域对 HS-IGA 评分的影响最大。因此,根据上半身或下半身区域中最大的病变数量,将区域组合成一个六点 IGA,得分 0(0-1 个病变)、1(2-5 个)、2(6-10 个)、3(11-15 个)、4(16-20 个)和 5(≥20 个病变)。测试-重测信度的组内相关系数为 0.91(95%置信区间 0.87-0.94)。HS-PGA 和化脓性汗腺炎临床反应(HiSCR)的 Spearman 秩相关系数分别为 0.73 和 0.51(两者比较均 P<0.001)。与皮肤病生活质量指数(DLQI)、疼痛数字评分量表和 HS-QoL 的 Spearman 秩相关系数分别为 0.42、0.34 和-0.25(所有比较均 P<0.001)。HS-IGA 在第 12 周和第 36 周具有反应性。与 HS-PGA(曲线下面积=0.89)和 HiSCR(曲线下面积=0.82)相比,预测性收敛效度非常好。与 DLQI 和 HS-QoL 相比,预测性发散效度较低。
HS-IGA 具有中等至较强的心理测量特性,计算简单。